To investigate how semaglutide affects different causes of death, researchers analyzed data from a trial of about 17,000 adults that ran from 2021 through 2023. The trial enrolled middle-aged adults who are overweight or obese, have cardiovascular disease and do not have diabetes.
Of the 833 deaths, 58% were related to cardiovascular issues and 42% were not. Among deaths not caused by cardiovascular conditions, infection was the most common cause, which occurred at a higher rate among the placebo group compared to semaglutide users.
“Semaglutide did not reduce incident COVID-19; however, among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19–related serious adverse events or died of COVID-19” compared to the placebo cohort, the researchers found.
Semaglutide patients also had lower rates of all-cause deaths, which the researchers associated with the weight loss drug reducing obesity-related health complications.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
